Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Conditions
Interventions
Tedizolid (BAY119-2631)
Placebo Tedizolid (BAY119-2631)
+2 more
Locations
55
United States
Chula Vista, California, United States
La Mesa, California, United States
Oceanside, California, United States
Las Vegas, Nevada, United States
Teaneck, New Jersey, United States
Wuhu, Anhui, China
Start Date
March 4, 2014
Primary Completion Date
March 6, 2016
Completion Date
April 18, 2016
Last Updated
June 7, 2017
NCT04263792
NCT06135350
NCT06322277
NCT06319235
NCT05824988
NCT05914467
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions